Ownership and insider activity for Adicet Bio, Inc. (ACET): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies.
Price
| Price | $9.05 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-05 | Klickstein Lloyd | A-Award | 18,300 | $168K |
| 2026-06-19 | Schor Chen | A-Award | 55,000 | $446K |
| 2026-06-19 | Aftab Blake | A-Award | 55,000 | $446K |
| 2026-06-21 | DUBIN STEVE | A-Award | 4,200 | $34K |
| 2026-06-21 | Chodakewitz Jeffrey | A-Award | 4,200 | $34K |
| 2026-06-21 | Grissinger Michael | A-Award | 4,200 | $34K |
| 2026-06-21 | Sinclair Andrew | A-Award | 4,200 | $34K |
| 2026-06-21 | Peng Katie | A-Award | 4,200 | $34K |
| 2026-06-21 | Klickstein Lloyd | A-Award | 4,200 | $34K |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | J-Other | 250,000 | $25 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.8M | $53.3M | $7.0M | $10.6M | $84.3M | $277.5M | $257.7M | $159.7M | $56.5M | $38.9M |
| Short-term Investments | $881000 | 0 | $101.0M | $51.8M | $10.3M | 0 | 0 | 0 | $119.8M | $119.6M |
| Receivables | $167.6M | 0 | 0 | $935000 | $2.7M | $214000 | $435000 | 0 | 0 | $342000 |
| Inventory | $98.1M | $136.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $352.7M | $54.2M | $109.5M | $64.2M | $100.3M | $282.4M | $261.0M | $162.3M | $180.1M | $160.9M |
| Property, Plant & Equipment | $10.0M | $39000 | $321000 | $2.1M | $25.9M | $35.0M | $49.0M | $44.2M | $36.8M | $28.5M |
| Goodwill | $67.9M | $237.0M | 0 | 0 | $20.1M | $19.5M | $19.5M | 0 | 0 | 0 |
| Intangible Assets | $79.1M | $285.1M | 0 | 0 | $1.2M | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $540.8M | $55.2M | $109.9M | $81.6M | $153.8M | $338.9M | $330.7M | $207.3M | $220.2M | $192.4M |
| Accounts Payable | 0 | $1.5M | $538000 | $1.1M | $1.6M | $3.3M | $4.4M | $2.6M | $4.8M | $4.7M |
| Short-term Debt | $197000 | $14.5M | 0 | 0 | $1.2M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $98.9M | $5.5M | $5.7M | $14.9M | $22.5M | $16.3M | $19.7M | $19.3M | $19.4M | $21.5M |
| Long-term Debt | $118.6M | $339.2M | $3.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $236.3M | $5.5M | $5.7M | $142.0M | $44.0M | $35.8M | $38.4M | $37.1M | $33.6M | $33.1M |
| Retained Earnings | $194.8M | -$33.8M | -$71.4M | -$69.6M | -$106.3M | -$168.3M | -$238.1M | -$380.8M | -$497.9M | -$614.7M |
| Total Equity | $304.4M | $49.7M | $104.2M | -$60.4M | $109.8M | $303.1M | $292.3M | $170.2M | $186.6M | $159.2M |
| Total Debt | $118.8M | $353.7M | $3.1M | 0 | $21.6M | $20.9M | $21.0M | $20.9M | $17.2M | $14.7M |
| Net Debt | $51.1M | $300.3M | -$104.9M | -$62.4M | -$73.0M | -$256.6M | -$236.6M | -$138.8M | -$159.1M | -$143.8M |
| Working Capital | $253.8M | $48.7M | $103.8M | $49.3M | $77.9M | $266.1M | $241.3M | $143.0M | $160.7M | $139.4M |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 6.71 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.65 |
Profitability
| Return on Equity | -74.90% |
| Return on Invested Capital | -77.98% |
| Return on Assets | -66.80% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACRV · ADAG · CRVO · GANX · HOWL · IMUX · IOBT
Explore sector: Healthcare · Biotechnology
More sections of ACET: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks